Drug Search Results
More Filters [+]

POLOXAMER-188 NF

Alternative Names: poloxamer-188 NF, P-188, Carmeseal-HF
Latest Update: 2024-04-24
Latest Update Note: News Article

Product Description

for the treatment of DMD in non-ambulatory patients; In multiple preclinical models, Carmeseal-MD, also known as Poloxamer-188 NF or P-188 NF, has been shown to seal the tears that characterize cellular membranes in Duchenne muscular dystrophy. Sealing of these tears leads to improved performance and prolonged survival of these cells, which translates into improved function of the heart, the diaphragm and skeletal limb muscle. (Sourced from: http://phrixuspharmaceuticals.com)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Phrixus Pharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for POLOXAMER-188 NF

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Muscular Dystrophy, Duchenne

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

P-004

P2

Terminated

Muscular Dystrophy, Duchenne

2021-09-01

24%

Recent News Events